StockData
NovaBridge Biosciences logo

NovaBridge Biosciences (NBP) stock

NBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 7, 2026Score 0/30
$0.83−0.05 (-5.66%)

Close on Nov 20, 2026Market cap $95.77MP/E –Yield –

NovaBridge Biosciences free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

NovaBridge Biosciences's free cash flow for the twelve months ending Dec 31, 2020 was CN¥425.55M. For fiscal 2023 it was -CN¥1.32B. The highest annual figure on record is CN¥425.55M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2023Dec 31, 2023-CN¥1.32B–
FY2022Dec 31, 2022-CN¥1.15B–
FY2021Dec 31, 2021-CN¥1.00B-335.7%
FY2020Dec 31, 2020CN¥425.55M–
FY2019Dec 31, 2019-CN¥880.22M–
FY2018Dec 31, 2018-CN¥295.11M–
FY2017Dec 31, 2017-CN¥272.48M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2020Dec 31, 2020CN¥1.01B–
Q4 FY2019Dec 31, 2019-CN¥223.61M–

More NovaBridge Biosciences figures

See a number that looks wrong?